N,α-Diethylphenethylamine

N,α-Diethylphenethylamine
Clinical data
Other names	DEPEA; NADEP; N,α-DEPEA; α,N-DEPEA; N,α-Diethylphenylethylamine; N,α-Diethylbenzeneethanamine; 2-Amino-N-ethyl-1-phenylbutane; 2-Ethylamino-1-phenylbutane; Ethyl(1-phenylbutan-2-yl)amine; EAPB; α-Et-EPEA
Legal status
Legal status	CA: Schedule I; DE: NpSG (Industrial and scientific use only); NZ: Class C; UK: Class A;
Identifiers
	IUPAC name N-Ethyl-1-phenylbutan-2-amine;
CAS Number	119486-07-6 ; 29805-52-5 (HCl);
PubChem CID	14833603;
ChemSpider	27101303;
UNII	7V4PP58Q6T;
CompTox Dashboard (EPA)	DTXSID501017073 ;
Chemical and physical data
Formula	C12H19N
Molar mass	177.291 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(C)NC(CC1=CC=CC=C1)CC;
	InChI InChI=1S/C12H19N/c1-3-12(13-4-2)10-11-8-6-5-7-9-11/h5-9,12-13H,3-4,10H2,1-2H3; Key:KHWYSUBVXWWBRB-UHFFFAOYSA-N;

N,α-Diethylphenethylamine (DEPEA or NADEP), also known as 2-ethylamino-1-phenylbutane (EAPB) is a stimulant drug of the phenylisobutylamine (α-ethylphenethylamine) group. It is a close chemical analog of methamphetamine, which has been sold as a designer drug. It was originally patented by Knoll Pharma as one of several analogs for pharmaceutical applications. In animal models these analogs showed properties of cognitive enhancement and increased pain tolerance. Nevertheless, this class of compounds was never developed into a medicine.